Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Biochemistry

Background:

• Tumor-initiating cells (TICs) are crucial for tumor recurrence and therapy resistance.
• Sphere cultures are investigated as a viable model system for TICs.
• Understanding TIC biology is key to developing more effective cancer treatments.

Purpose of the Study:

• To validate sphere cultures as models of TICs.
• To identify molecular pathways upregulated in TICs.
• To investigate the therapeutic potential of mitocans against TICs.

Main Methods:

• Microarray and microRNA data analysis of sphere cultures and TICs.
• Analysis of Trp pathway enzymes and transporters (IDO1, CD98, LAT1).
• In vivo serial transplantation assays and treatment with mitocans (α-tocopheryl succinate, MitoVES).

Main Results:

• Sphere cultures confirmed as valid TIC models across breast, prostate, mesothelioma, and glioblastoma.
• The Trp pathway, particularly indoleamine-2,3-dioxygenase-1 (IDO1), was significantly upregulated in all TICs.
• TICs showed increased expression of the Trp uptake system (CD98/LAT1).
• IDO1 levels increased with serial transplantation and were suppressed by mitocans, including MitoVES.
• MitoVES demonstrated efficacy in TICs from primary human glioblastomas.

Conclusions:

• Sphere cultures serve as reliable models for studying TICs.
• IDO1 is a key enzyme in TICs, regulated transcriptionally and post-transcriptionally.
• Mitocans, especially MitoVES, show promise in suppressing IDO1 in TICs, offering a potential therapeutic strategy.